MEDICINES INCLUDED

78 medicines. 12 genes. One report.

Every medicine in your report carries fully actionable advice from the Dutch Pharmacogenetics Working Group (DPWG), so your doctor can rely on it to guide prescribing.

medicines

genes

areas of medicine

SEARCH THE LIST

Is my medicine included?

Showing 12 of 78. Search by medicine name, condition or gene.

Showing 13 of 78.

Medicine	Used for	Gene	What your report guides	Area
Sertraline	Depression, anxiety	CYP2C19	Starting dose	Mental health
Clopidogrel	Stroke, heart attack	CYP2C19	Whether it will work	Heart & circulation
Codeine	Pain	CYP2D6	Effectiveness and safety	Pain
Simvastatin	High cholesterol	SLCO1B1	Muscle side-effect risk	Heart & circulation
Atorvastatin	High cholesterol	SLCO1B1	Dose or alternative	Heart & circulation
Citalopram	Depression, anxiety	CYP2C19	Maximum daily dose	Mental health
Escitalopram	Depression, anxiety	CYP2C19	Maximum daily dose	Mental health
Amitriptyline	Nerve pain, migraine	CYP2D6 CYP2C19	Dose or alternative	Pain
Atomoxetine	ADHD	CYP2D6	Dose adjustment	Mental health
Warfarin	Blood clots	CYP2C9 VKORC1	Starting dose	Heart & circulation
Tramadol	Pain	CYP2D6	Effectiveness	Pain
Omeprazole	Acid reflux	CYP2C19	Dose	Digestion
Lansoprazole

GENES TESTED

The 12 genes we test

Some genes change how your body processes a medicine; others change how your body responds to it.

CYP2D6

Processes codeine, tramadol and many antidepressants.

CYP2C19

Affects Clopidogrel, several antidepressants and stomach-acid medicines.

CYP2C9

Affects warfarin and some diabetes and anti-inflammatory medicines.

VKORC1

Changes how sensitive you are to warfarin.

SLCO1B1

Controls how statins reach the liver; linked to statin muscle pain.

CYP3A5

Affects tacrolimus, used after organ transplant.

CYP2B6

Affects efavirenz and some other medicines.

DPYD

Important for the safety of some chemotherapy medicines.

TPMT

Affects thiopurines such as azathioprine.

UGT1A1

Affects irinotecan and atazanavir.

HLA-B

Flags the risk of serious reactions to certain medicines.

Factor V Leiden: relevant to oestrogen-containing medicines.

Gene list follows the UPGx panel published in The Lancet (2023). To be confirmed by Mantara before launch.

NOT ON THE LIST?

The panel grows as the evidence grows

We only include medicines with fully actionable guidance, so every result is meaningful. The list is likely to grow quickly. If your medicine is not included, contact us and we’ll tell you whether it may be added.